STAT+: BioSpring Partners closes $245 million first fund as private markets tense up
When Michelle Dipp and Jennifer Lum decided to launch a life sciences growth equity fund two years ago, the market looked very different.
The Covid-19 pandemic was driving investors in droves to biotech and pharma companies. Automation and drug manufacturing were becoming hot topics.
